Senseonics Holdings

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Senseonics achieves FDA milestone with Eversense 365, focuses on growth

Senseonics had a pivotal quarter with FDA approval of Eversense 365, driving positive feedback and strong adoption.
Financially, the company reported Q3 net revenue of $4.3 million with a gross loss of $4.1 million, focusing on cost reduction.
Efforts to reduce operating expenses and extend cash runway aim to address financial challenges and enhance stability.
With opportunities to accelerate sales, improve diabetes management, and expand market reach, Senseonics is poised for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations Tim Goodnow – President and Chief Executive Officer Rick Sullivan – Chief Financial Officer Conference Call Participants Colin Clark – Stifel Sam Eiber – BTIG Operator Good day, and welcome to the Senseonics Third Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

Senseonics Holdings, Inc. (SENS) Q3 2022 Earnings Call Transcript

Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results

First patients have been served, launching the Nurse Practitioner Group partnership to expedite and expand access to the Eversense® E3 CGM GERMANTOWN, Md. , Nov. 3, 2022 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® CGM Systems,  today announced the launch of a collaboration with the Nurse Practitioner Group (NPG), a leader in multidisciplinary health services and medical staffing solutions.

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)

Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time

MicroVision

PaxMedica Inc

SelectQuote

Hot penny stocks to buy for under $5 but are they worth the risk? The post Penny Stocks To Buy: 4 Stocks Under $5 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 4 Stocks Under $5 To Watch This Week

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. Management is scheduled to participate on Tuesday, September 13, 2022, at 7:20 am ET and will hold one-on-one meetings following. In

Senseonics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced its Chief Financial Officer, Nick Tressler, is transitioning from his position, effective September 1, 2022. Rick Sullivan, Senseonics' current Vice President of Finance, has been appointed to succeed Mr. Tressler as Chief Financi

Senseonics Announces CFO Transition

The partnership between Senseonics Holdings and Elevance Health (formerly Anthem) is expected to increase coverage to Senseonics' implantable CGM systems including Eversense. Senseonics plans to introduce new diabetes management systems as well as doctors and patients to the Eversense E3 product offering.

Senseonics Holdings: Planning To Increase Revenue After FDA System Approval

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Showcase, taking place virtually. Management is scheduled to present on Wednesday, August 31, 2022 at 3:00pm ET. Interested parties can access a live and recorded

Senseonics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Senseonics (SENS) recently announced its Q2 2022 financial results. These are the details.

Senseonics (SENS) Q2 2022 Earnings Highlights

Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Tim Goodnow - President and Chief Executive Officer Nick Tressler - Financial Officer Mukul Jain - Chief Operating Officer Conference Call Participants Sam Eiber - BTIG Alex Nowak - Craig-Hallum Capital Group Operator Good day and welcome to the Senseonics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q2 2022 Results - Earnings Call Transcript

Senseonics (SENS) delivered earnings and revenue surprises of 25% and 12.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2022. Recent Highlights & Accomplishments: Achieved CE mark approval for the Eversense E3 6-month CGM System with exceptional accuracy and reduced calibration planned for Europea

Senseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results

Senseonics (NYSEAMERICAN: SENS ) stock jumped by over 50% after it announced its Eversense implantable glucose monitor was approved for coverage by Elevance Health (NYSE: ELV ), formerly known as Anthem. Senseonics had revenue of just $2.5 million in the first quarter.

Why Is Senseonics (SENS) Stock Heating Up Today?

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System. Anthem's decision will add more than 45 million covered lives for the long-term implantable CGM system to help manage their diabetes.

Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. Management will hold a conference call to review the Company's second quarter 2022 performance starting at 4:30 p.m.

Senseonics Holdings, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 9, 2022, at 4:30 p.m. Eastern Time

Sesen Bio Inc.

Titan Pharma

Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which Industries Are Penny Stocks Investors Watching Right Now

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has received CE Mark approval for the next-generation Eversense® E3 CGM System, the longest-lasting system available, with exceptional accuracy. The CE Mark approval confirms that the Eversense E3 meets the requirements of

Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System

Cinedigm

Guardion Health Sciences Inc

Ideanomics Inc

McEwen Mining

Romeo Power

Seanergy Maritime Hlds

These seven undervalued penny stocks each have the potential to pay off for investors down later down the road. The post 7 Undervalued Penny Stocks to Buy for Massive Gains appeared first on InvestorPlace.

7 Undervalued Penny Stocks to Buy for Massive Gains

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming hybrid H.C. Wainwright Global Investment Conference. Management is scheduled to participate virtually and hold one on-one-meetings Tuesday, May 24, 2022. An on-demand presentation webcast will

Senseonics to Participate in the H.C. Wainwright Global Investment Conference

Senseonics Holdings, Inc. (NYSE:SENS ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Malcolm MacLeod - Investor Relations Timothy Goodnow - President & Chief Executive Officer Nick Tressler - Chief Financial Officer, Secretary & Treasurer Conference Call Participants Colin Clark - Stifel Sam Eiber - BTIG Alex Nowak - Craig-Hallum Operator Good day, and welcome to the Senseonics First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note today's event is being recorded.

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q1 2022 Results - Earnings Call Transcript

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2022. Recent Highlights & Accomplishments: Received approval from the Food and Drug Administration (FDA) for the Eversense® E3 CGM System (“E3”), offering industry leading 6-mon

Senseonics Holdings, Inc. Reports First Quarter 2022 Financial Results

Diebold Nixdorf Inc

Mattel

The unprecedented expansionary fiscal and monetary policies during the pandemic may have caused a significant surge in zombie companies. The post 3 Zombie Companies That Still Have Hope for New Life appeared first on InvestorPlace.

3 Zombie Companies That Still Have Hope for New Life

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2022 financial results after market close on Tuesday, May 10, 2022. Management will hold a conference call to review the Company's first quarter 2022 performance starting at 4:30 p.m.

Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022, at 4:30 p.m. Eastern Time

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, its commercialization partner, have announced the first commercial patient has been implanted with Eversense® E3, kicking off the launch of the next-generation CGM System in the U.S. The Eversense E3 Sensor was approve

News for Senseonics Holdings Stock (SENS)